Monday, May 12, 2025
spot_img

Syensqo – Acquisition of own shares

Acquisition of own shares

Brussels, Belgium – May 12, 2025 – 17:45 CET

In accordance with article 7:215 of the Belgian Code of Companies and Associations, Syensqo SA (“Syensqo” or the “Company”) pursues its Share Buyback Program (or the “Program”) announced on September 30, 2024, covering up to €300 million.

This third tranche began on February 27, 2025 and will run until June 27, 2025 at the latest, and will cover a maximum amount of up to €50 million (of the €300 million Program). The Company intends to cancel all shares acquired through this tranche.

In the framework of this tranche, Syensqo announces that it has repurchased 44,671 Syensqo shares in the period from May 05, 2025 up to and including May 09, 2025, as follows: 

Date of purchase Market / MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€)
05-May-25 CEUX 4,464 64.02 285,791.98 63.68 64.38
05-May-25 XBRU 4,160 63.99 266,201.31 63.62 64.40
06-May-25 CEUX 4,221 63.55 268,274.10 63.06 63.92
06-May-25 XBRU 4,531 63.60 288,186.55 63.14 64.24
07-May-25 CEUX 5,780 63.40 366,458.94 62.9 63.94
07-May-25 XBRU 3,923 63.42 248,817.06 63.04 63.94
08-May-25 CEUX 4,672 63.22 295,402.62 62.6 63.66
08-May-25 XBRU 4,352 63.17 274,929.77 62.44 63.62
09-May-25 CEUX 4,218 64.13 270,534.08 63.8 64.7
09-May-25 XBRU 4,350 64.27 279,591.47 63.88 64.78
Total   44,671   2,844,187.87    

As of May 09, 2025, the Company held a total of 1,414,995 own shares, spread out as follows:

  • 17,592 Syensqo shares in the framework of the third tranche of the ongoing €300 million Program that started on November 5, 2024; 
  • 746,031 Syensqo shares in the framework of the LTIP Share Buyback Program that ended on October 23, 2024;
  • 651,372 Syensqo shares by Syensqo Stock Option Management SRL (“SSOM”), a wholly owned indirect subsidiary of the Company.

Contacts

Investors & Analysts
[email protected]
Media
[email protected]
Sherief Bakr
Bisser Alexandrov
Loïc Flament
Robin Moore- Randolph
+44 7920 575 989
+33 607 635 28
+32 478 69 74 20
+1 470 493 2433

 

Perrine Marchal
Laetitia Schreiber
+32 487 74 38 07
+32 478 32 62 72

Safe harbor

This press release may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this press release is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&I projects and other unusual items. Consequently, actual results or future events may differ materially from those expressed or implied by such forward-looking statements. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

About Syensqo 

Syensqo is a science company developing groundbreaking solutions that enhance the way we live, work, travel and play. Inspired by the scientific councils which Ernest Solvay initiated in 1911, we bring great minds together to push the limits of science and innovation for the benefit of our customers, with a diverse, global team of more than 13,000 associates. 
Our solutions contribute to safer, cleaner, and more sustainable products found in homes, food and consumer goods, planes, cars, batteries, smart devices and health care applications. Our innovation power enables us to deliver on the ambition of a circular economy and explore breakthrough technologies that advance humanity.

Investor Relations sources

  • Earnings materials
  • Strategy
  • Share information
  • Credit information
  • Separation documents
  • Webcasts, podcasts and presentations
  • 2023 Annual Integrated Report
  • Subscribe to our distribution list

Attachment

  • 20250512_Acquisition of shares_EN

Powered by SlickText.com

Hot this week

Team, Inc. Reports First Quarter 2025 Results

SUGAR LAND, Texas, May 12, 2025 (GLOBE...

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) --...

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

First of several clinical updates through mid-2026 accepted for...

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

KEY HIGHLIGHTS First patient expected to start therapy...

Topics

spot_img

Related Articles

Popular Categories

spot_img